On Wednesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Voltari Corporation, (NASDAQ:VLTC), Dyax, (NASDAQ:DYAX), Nymox Pharmaceutical Corporation, (NASDAQ:NYMX), GODADDY, (NYSE:GDDY)
Voltari Corporation, (NASDAQ:VLTC), with shares skyrocketed 147.52%, closed at $2.50.
Dyax, (NASDAQ:DYAX), with shares jumped 53.69%, settled at $25.75, hitting new 52-week high of $26.11.
Nymox Pharmaceutical Corporation, (NASDAQ:NYMX), with shares climbed 49.64%, and closed at $1.26.
GODADDY, (NYSE:GDDY), gained 30.75%, and closed at $26.15, hitting new 52-week high of $26.84.
Latest NEWS regarding these Stocks are depicted underneath:
Voltari Corporation (NASDAQ:VLTC)
On Monday, Voltari Corporation (VLTC), declared recently that it has closed its formerly declared offering of transferable subscription rights to purchase up to an aggregate of 4,300,000 shares of the Corporation’s ordinary stock, $0.001 par value per share. The Rights Offering was launched on February 27, 2015, to stockholders of record on February 3, 2015, and expired at 5:00 p.m., New York City time, on March 20, 2015.
The Rights Offering was fully subscribed and, as such, the Corporation issued 4,300,000 shares of its ordinary stock for total net proceeds of $4.6 million, after fees and expenses.
The shares of Ordinary Stock subscribed for in the Rights Offering will be distributed to subscribers or credited through DTC on or about March 30, 2015. Any excess subscription payments to be refunded to subscribers will be mailed by the subscription agent as promptly as practicable.
Voltari empowers its customers (counting brands, marketers and advertising agencies) to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, digital marketing and advertising solutions, primarily over smartphones and other mobile devices.
Dyax Corp. (NASDAQ:DYAX)
Dyax Corp. (DYAX), surged Wednesday because of the declaration of its positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.
Recently Dyax also declared receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for HAE.
“The positive results from this trial are a noteworthy milestone for Dyax and will be integral in guiding the future clinical development of DX-2930,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “If approved, we believe that DX-2930, with its unique profile, is well positioned as a potential preventive treatment option for patients suffering from HAE.”
Dyax Corp., a biopharmaceutical corporation, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Nymox Pharmaceutical Corporation (NYMX), declared that the Corporation is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will comprise new long-term data from Studies NX02-0017 and NX02-0018. The Corporation anticipates to provide these new pivotal Phase 3 study results in Q2 or early Q3 this year.
The pivotal U.S. studies NX02-0017 and NX02-0018 were initiated in 2009. Enrollment of NX02-0017 (499 patients randomized) was accomplished in 2012; enrollment of NX02-0018 (498 patients randomized) was accomplished in 2013. 973 patients were injected with either NX-1207 2.5 mg (n=582) or saline vehicle alone as control (n=391). At 12 months post-treatment there was no overall top-line statistical significance for the efficacy of treatment in terms of BPH Symptom Score improvement VS controls. The safety profile of NX-1207 was excellent.
Nymox Pharmaceutical Corporation, a biopharmaceutical corporation, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, in addition to AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimer’s disease.
GODADDY INC. (NYSE:GDDY)
GODADDY INC. (GDDY), made its debut on Wednesday and surged. Before its debut, the world’s largest technology provider dedicated to small businesses, declared the pricing of its initial public offering of 23,000,000 shares of its Class A ordinary stock at a price to the public of $20.00 per share. This comprises 2,500,000 shares of Class A ordinary stock that are being purchased at the initial public offering price by certain entities associated with the principal beneficial holders of its Class A ordinary stock. All of the shares are being offered by GoDaddy. In addition, GoDaddy has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Class A ordinary stock to cover over-allotments, if any.
GoDaddy Inc. focuses on the design and development of cloud-based technology products for small businesses, Web design professionals, and individuals. Its products would enable its customers to establish a digital presence, connect with their customers, and manage their business operations. The corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
